FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 08:45:42 23/05/2024 BST | ||
| 9.14 EUR | -1.08% |
|
| Current month | -32.75% | ||
| 1 month | -28.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 9.14 | -1.08% |
| 22/05/24 | 9.24 | -3.85% |
| 21/05/24 | 9.61 | +4.46% |
| 20/05/24 | 9.2 | -1.18% |
| 17/05/24 | 9.31 | -3.62% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 08:45 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LE |
| ISIN | DE000HD33LE4 |
| Date issued | 27/02/2024 |
| Strike | 596.7 $ |
| Maturity | Unlimited |
| Parity | 15.56 : 1 |
| Emission price | 10.27 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.23 € |
|---|---|
| Lowest since issue | 9.13 € |
| Spread | 0.09 € |
| Spread % | 0.97% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
